Use of abciximab-Modified Thrombelastography in Patients Undergoing Cardiac Surgery
Authors:
- S. C. KettnerSKS. C. Kettner
- O. P. PanzerOPO. P. Panzer
- S. A. KozekSKS. A. Kozek
- F. A. SeibtFSF. A. Seibt
- B. StoiserBSB. Stoiser
- J. KoflerJKJ. Kofler
- G. J. LockerGLG. J. Locker
- M. ZimpferMZM. Zimpfer
- 1 September 1999
- journal article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 89 (3) , 580
Abstract
Thrombelastography (TEG) is a reliable coagulation monitoring system that can guide blood product transfusion in cardiac surgery. The maximum amplitude (MA) of TEG measures clot strength, which is dependent on both fibrinogen level and platelet function. Inhibition of platelet function with abciximab-fab is suggested to permit quantitative assessment of the contribution of fibrinogen to clot strength. We hypothesized that abciximab-modified TEG permits prediction of plasma fibrinogen levels and that the difference of standard MA and abciximab-modified MA (ΔMA) is a correlate for platelet function. We correlated abciximab-modified MA with plasma fibrinogen levels and ΔMA with platelet count in patients undergoing coronary revascularization. Correlation between plasma fibrinogen levels and abciximab-modified MA was significant (adjusted r2: 0.8; P < 0.0001). Correlation of ΔMA with platelet count was not significant when calculated in millimeters (adjusted r2: 0.04; P = 0.73). However, when ΔMA was calculated in dynes per square centimeter (ΔGMA), it correlated significantly with platelet count (adjusted r2: 0.51; P < 0.0001). We conclude that abciximab-modified TEG may therefore help to discriminate between hypofibrinogenemia and platelet dysfunction as a cause of decreased MA. Implications We examined the use of abciximab-modified thrombelastography in patients undergoing cardiac surgery. Modification of thrombelastography with abciximab-fab allows prediction of fibrinogen levels, despite coagulation altered by cardiac surgery. The difference of standard maximum amplitude and abciximab-modified maximum amplitude correlates with platelet function when expressed in dynes per square centimeter.Keywords
This publication has 21 references indexed in Scilit:
- ACCURACY OF NATIVE AND ACTIVATED THROMBELASTOGRAPHY FOR ASSESSMENT OF PLASMA FIBRINOGEN LEVELSAnesthesiology, 1998
- Monitoring platelet glycoprotein IIb/IIIa—fibrin interaction with tissue factor—activated thromboelastographyJournal of Laboratory and Clinical Medicine, 1997
- A452 CAN THROMBOELASTOGRAPHY ESTIMATE PLASMA FIBRINOGEN LEVELAnesthesiology, 1997
- A Modified Thromboelastographic Method for Monitoring c7E3 Fab in Heparinized PatientsAnesthesia & Analgesia, 1997
- Shear-Induced Platelet Aggregation Is Inhibited by In Vivo Infusion of an Anti–Glycoprotein IIb/IIIa Antibody Fragment, c7E3 Fab, in Patients Undergoing Coronary AngioplastyCirculation, 1995
- Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypassThe Annals of Thoracic Surgery, 1994
- Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assayJournal of Cardiothoracic and Vascular Anesthesia, 1994
- Reduction of heparin binding to and inhibition of platelets by aprotininThe Annals of Thoracic Surgery, 1993
- Platelet adhesion to fibrin(ogen)Blood Coagulation & Fibrinolysis, 1993
- Blutgerinnungsstudien mit der Thrombelastographie, einem neuen UntersuchungsverfahrenJournal of Molecular Medicine, 1948